Systems and methods for the treatment of hemoglobinopathies
Abstract:
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.
Public/Granted literature
Information query
Patent Agency Ranking
0/0